John Houston
Chief Executive Officer at ARVINAS, INC.
Net worth: 43 M $ as of 2024-03-30
Profile
John G. Houston holds the position of President, Chief Executive Officer & Director at Arvinas, Inc. and President, Chief Executive Officer & Director at Arvinas Operations, Inc. (a subsidiary of Arvinas, Inc.). He is also on the board of NextCure, Inc., Cybrexa, Inc. and Oerth Bio LLC. John G. Houston previously occupied the position of Senior Vice President-Specialty Discovery at Bristol Myers Squibb Co. and Head-Lead Discovery Unit at GlaxoSmithKline Research & Development Ltd. He received a doctorate from the University of Glasgow and a doctorate from Heriot-Watt University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ARVINAS, INC.
1.52% | 2024-02-22 | 1,036,681 ( 1.52% ) | 43 M $ | 2024-03-30 |
NEXTCURE, INC.
-.--% | 2023-06-21 | 0 ( -.--% ) | - $ | 2024-03-30 |
John Houston active positions
Companies | Position | Start |
---|---|---|
ARVINAS, INC. | Chief Executive Officer | 2017-08-31 |
NEXTCURE, INC. | Director/Board Member | 2020-09-09 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Chief Executive Officer | 2017-09-20 |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Director/Board Member | 2019-09-02 |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky. | Director/Board Member | - |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Connecticut United for Research Excellence, Inc. intends to promote public understanding on the benefits of vaccines and medicines that are being offered by bioscience companies. Its members include biomedical research and educational institutions, biotechnology companies, health professionals, and healthcare systems. The company was founded on August 31, 1990 and is headquartered in New Haven, CT. | Director/Board Member | - |
Bioct Innovation Commons | Director/Board Member | - |
Former positions of John Houston
Companies | Position | End |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2016-07-31 |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, GlaxoSmithKline Research & Development Ltd. is a British biopharma company that unites science, technology, and talent to get ahead of disease together. The private company was founded in 1965 and is based in Brentford, UK. GSK's work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer and Shionogi as shareholders. The company is united to do better in various fields, from finance to communications, procurement to HR. GSK provides images and B-roll video for media use and has a privacy notice that applies to any individual who is a current or former registered shareholder of GSK plc. | Corporate Officer/Principal | - |
Training of John Houston
University of Glasgow | Doctorate Degree |
Heriot-Watt University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ARVINAS, INC. | Health Technology |
NEXTCURE, INC. | Health Technology |
Private companies | 6 |
---|---|
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Connecticut United for Research Excellence, Inc. intends to promote public understanding on the benefits of vaccines and medicines that are being offered by bioscience companies. Its members include biomedical research and educational institutions, biotechnology companies, health professionals, and healthcare systems. The company was founded on August 31, 1990 and is headquartered in New Haven, CT. | Commercial Services |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, GlaxoSmithKline Research & Development Ltd. is a British biopharma company that unites science, technology, and talent to get ahead of disease together. The private company was founded in 1965 and is based in Brentford, UK. GSK's work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer and Shionogi as shareholders. The company is united to do better in various fields, from finance to communications, procurement to HR. GSK provides images and B-roll video for media use and has a privacy notice that applies to any individual who is a current or former registered shareholder of GSK plc. | Commercial Services |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky. | Health Technology |
Bioct Innovation Commons |
- Stock Market
- Insiders
- John Houston